Antibacterial Products in Clinical Development for Priority Pathogens 2019 | NLM

Disaster Information Management Research Center | NLM

Antibacterial Products in Clinical Development for Priority Pathogens 2019

11/01/2019 12:00 AM EDT

Source: World Health Organization (WHO). Published: 11/2019. This web page provides information and data results from the World Health Organization (WHO) analysis of the pipeline of antibacterial products (antibiotics and biologicals) that were in phase I-III of clinical development (as of September 2019) and which had not, at that date, received market authorization for human use anywhere in the world. The analysis matched the products in development against the WHO priority pathogens list (PPL), Mycobacterium tuberculosis, and Clostridium difficile. (Text)